

Innovating with the Mid-Atlantic Federal Labs Richard A. Bendis

President & CEO

8/28/2012 Cambridge, MD

www.BioHealthInnovation.org



State of Maryland: Federal Resources

 Maryland Federal R&D investment exceeding \$12 billion annually



 59 Federal Laboratories, Centers, & Institutes in Maryland



"The Region"--Central Maryland

Unrivaled Research Assets Unfulfilled Commercial Promise














National Leadership



President Obama:

- Bioeconomy Initiatives
- America Invents Act (2011)

- America Invents Act
- Center for Advancing Translational Sciences in NIH to advance commercialization (NCATS)
- Develop a National Bioeconomy Blueprint
 - Support R&D investments
 - Facilitate the transition from research lab to market
 - Reduce barriers, increase speed and predictability of regulatory process, and reduce cost.
 - Update training programs and align academic institutions incentives
 - Identify and support the development of PPPs and pre-competitive collaborations



State Leadership



Maryland Governor O'Malley:

- BioMaryland 2020
- Invest Maryland
- Maryland Biotechnology Investment Tax Credit (\$6 m/yr)
- BioMaryland 2020 blueprint
- Invest Maryland (\$70 million)
- Maryland Life Sciences Advisory Board
- The Maryland Venture Fund
- Maryland Innovation Initiative



Local Leadership



County Executive Ike Leggett:

- Accelerate innovation & grow tax base
- Create a regional Montgomery County / Baltimore Innovation Intermediary
- Support life science centers in the region



great seneca science corridor master plan









Challenges to Innovation Economy

Lack of connection of innovation resources

Lack of an entrepreneurial culture and C-level executives

Lack of early-stage funding for commercializing technologies

Lack of a STEM Workforce

BHI Value Proposition

Connects regional innovation assets

Develops an entrepreneurial talent and support pipeline

Attracts funding for technology commercialization

Develops a continuum of innovation workforce



BioHealth Regional Innovation Cluster Assets













































National Biodefense Analysis and Countermeasures Center















What is A Regional Innovation Intermediary?


- An organization at the Center of the region's, state's and country's efforts
 - Align local technologies, assets and resources
 - Advance Innovation



- Regionally-oriented
- Private-public partnership,
 501(c)(3) nonprofit
- Market-driven, private sector-led
- Neither a government initiative, nor a membership organization



BHI: An Innovation Intermediary that Connects Sectors, Industries, Communities, & Markets





Regional BioHealth Ecosystem Partners

ACADEMIA

- RESEARCH/T2
- LIFELONG LEARNING
- ECONOMIC DEVELOPMENT

INDUSTRY

- PROFIT
- PROCESS
- PRODUCT

INSEPARABLE MISSIONS

GOVERNMENT

- Sustainability
- FEDERAL LABORATORIES
- INFRASTRUCTURE SUPPORT
 - ECONOMIC POLICY

FOUNDATIONS

- Economic Growth
- COMMUNITY INVESTMENT
- REGIONAL COLLABORATION



BHI Partners and Sponsors







































BHI Board of Directors



Michael J. Baader, Esq.

Managing Director, Venable LLP



Richard Bendis

President & CEO, BioHealth Innovation, Inc.



Scott Carmer (Chair)

Executive Vice President of Commercial Operations, MedImmune



Kenneth Carter

Chair, Noble Life Sciences



Scott Dagenais

Senior Vice President, M&T Bank



Ronald J. Daniels

President, Johns Hopkins University



David M. Gillece (Secretary)

Regional Managing Principal, Cassidy Turley



William E. Kirwan

Chancellor, University System of Maryland



Douglas Liu

Senior Vice President of Global Operations, Qiagen



David Mott

General Partner, New Enterprise Associates



Jerry Parrott

Vice President, Corporate Communications and Public Policy, Human Genome Sciences



Jay Ridder

Office Managing Partner, Ernst & Young



William G. Robertson (Treasurer)

President & CEO, Adventist Healthcare



J. Thomas Sadowski

President & CEO, Economic Alliance of Greater Baltimore




Thomas Street

Assistant Chief Administrative Officer, Montgomery County Government



BHI Organizational Chart





BHI/EIR Technology Focus

- Therapeutics
- Diagnostics
- Medical Devices
- Healthcare Services
- E-Health
- Mobile Health
- Electronic Medical Records
- Health Informatics
- BioHealth Cyber Security







Innovation Paradigm Shift

PROOF OF CONCEPT
(Technological Feasibility)
Laboratory Push

"It Works!"






PROOF OF COMMERICAL RELEVANCE (Market Pull)

"It Works To Solve A Problem"
"I'll Buy It"





Innovation Capital "VALLEY OF DEATH"





Central Maryland

Innovation Capital IVIap Capital Sources by Investment Stage					
Pre-Proof of Concept \$25K - \$1.5M (over 5 years)	Translational Research / Proof of Concept \$15K - \$2M	Proof of Commercial Relevance / Pre-Seed \$50K - \$500K	Seed / Start-Up \$50K - \$1M	Early Stage \$250K - \$2M	Later Stage \$2M+
NIH R01 NIH R03 NIH R21 Small Business Technology Transfer Research Grant (STTR) Phase I Innovate Maryland Funding Type Key	Research Grant (SBIR) Phase I Maryland Stem Cell Research Fund (MSCRF) TEDCO University Technology Development Fund (UTDF) TEDCO TechStart Maryland Biotechnology Center's Translational Research Award Association of University Re	echnology Managers (AUTM)	 Dingman Center Angels (UMD) TEDCO Johnson & Johnson Joint Investment Program Propel Baltimore Fund SBIR / STTR Phase II BHI Central Maryland Angel Fund National Association of Seed & Venture Funds (NASVF) Angel Capital Association (ACA) 	Development Corporation (MHCPDC) Invest Maryland: Maryland Venture Fund	Maryland Venture Fund Authority ABS Capital Partners Greenspring Associates Novak Biddle Venture Partners Sterling Venture Partners Harbert Venture Partners JMI Equity National Venture Capita Association (NVCA)
AcademicB	ioHealth Innovation, In	IC.		Mid-Atlantic Venture Associa	ation (MAVA)
Accelerator In	novation-based Economic evelopment (IBED)				

Maryland Biotechnology Investor Tax Credit

Montgomery County Biotechnology Investor Tax Credit




State of Maryland

Venture Capital

Associations


Federal

How does BHI work? Commercialization Pipeline





BHI Commercialization Model



Partnership Intermediary Agreements (PIA)



Transfer (OTT) that supports the 27 NIH institutes' \$3 billion intramural research and the Food and Drug Administration to promote and foster cooperative research and accelerate technology commercialization among NIH/FDA, businesses, and universities.



- PIA between BHI and the Telemedicine & Advanced
 Technology Research Center (TATRC) to capture
 USAMRMC and TATRC research outcomes and promote
 further research, product development,
 commercialization, and economic development
 opportunities.
 - TATRC has funded 241 MD based projects over the last 12 years.




Entrepreneur-in-Residence (EIR)

Proactively identifies and commercializes **market-relevant** intellectual properties from:

- Federal Labs
- Universities
- Private Sector

Progress (3 ½ months into Program)



- 7 Progressed to Secondary Analysis in BHI Pipeline (Safety & Efficacy Profiling, IP Diligence, Regulatory & Development Pathways)
- 26 No BHI Interest, 22 still Under Review



Todd Chappell



Entrepreneur-in-Residence (EIR)

- Identify market viable biohealth assets
- Act as liaison among federal labs, academic, industry, venture capital, and non-profit
- Detailed commercial evaluation of most valuable technologies
- Provide early-stage developmental strategies
- Nurture relationships with scientists, mentor to ensure research becomes commercially valuable, and track progress
- Identify creative funding to advance exciting, novel technologies
- Create new BioHealth companies



EIR Criteria

- Senior management in an early stage life sciences startup
 - Entrepreneurial life science start up or spin out activity
- Management in a organization that specializes in startup companies
- Experience in a seed stage venture capital firm
- Served in a business development role in a high performing university or business development organization that successfully formed new ventures
- Served in a business development role, product development role, or other capacities for biotech products or services that enable substantial knowledge of the earliest stages of development for a new technology startup company



EIR Expectations



- Assist OTT in the evaluation of existing technologies
- Provide an entrepreneurial perspective to OTT in its evaluation of new licensing proposals
- Advise OTT on opportunities for new ventures based on NIH/FDA technologies
- Assist with developmental strategies

commercially valuable

 Mentor scientists to help ensure their research becomes



- Identify market viable innovations from NIH and other regional institutions
- Act as liasion among regional biohealth stakeholders and NIH
- Primary and secondary commercial analysis of lead technologies
- Develop novel technologies that are at conceptual stage
- Act as catalyst to license most interesting technologies and fund start-up companies

Example of EIR Interaction

INNOVATEMaryland's Innovation Initiative

- \$5.8M budget
- 5 University partners
- 5 University site miners
- 40 University pre proof-ofconcept technologies funded
- \$25-\$150K funded per technology



- Regular meetings between BHI/EIR and site miners
- BHI identifies most commercially relevant technologies
- BHI and INNOVATE MD partnership opportunities



EIR Integration into NIH System

- Office at the central Office of Technology Transfer (OTT)
 - Volunteer status
 - Report to Director and Deputy Director of centralized OTT
 - Full access to NIH campus and staff
- Active participant in Technology Review Groups at top three institutions
 - Review of patent prosecution decisions for new and existing inventions
- Active participant in Technology Development Coordinator meetings
 - Key decisions on selected technologies
- Access to database (SYNAPSE) detailing invention filings





NIH Overview

- Intramural budget is approximately \$3B per year
 - 6,000 scientists
 - 27 institutes and centers (ICs)
- Three largest centers: NCI, NIAID, and NHLBI
 - In aggregate represents more than half of invention filings
- Centralized Office of Technology Transfer
 - Responsible for patenting
 - Technology transfer specialist at each institution
 - ~150 licensing staff members at NIH



Early-Stage Analysis of Commercial Relevance







Key Considerations for Technology Focus

- Clear unmet need that benefits public health
- First-in-class, best-in-class therapies
- Target therapeutic areas that reflect strategic objectives
- Clinical development advantage
- Relevance to strategic needs



What is the Overall Process for Licensing / Creating Company?

Industry Needs

- BHI Board
- Venture Capital
- Regional Pharma / Biotech
- Literature
- Personal Network

Identification

- Scientists
- Tech transfer
- NIH review meetings
- NIH Licensing Managers
- NIH database

Market Analysis

- Primary: Literature
- Secondary: KOLs
- Development strategy
- Scientific/commercial validation with internal and external experts

Funding

- IC (e.g. NCATS)
- SBIR-TT
- CRADA
- TEDCO
- Innovate MD
- Invest MD
- BioHealth Innovation
- Angel funding
- Venture capital



BHI Commercialization Pipeline

STEP I: Innovation Exposures / Sourcing

- Federal Labs
- Academia
- Investor Groups
- Industry
- Personal
 Networks

STEP II: Screening

- Stage of Development
- IP Status
- Level of unmet medical need
- Industry interest
- Market size
- Competitive Advantage
- Scientific Reputation

STEP III: Secondary Analysis

- DiseaseOverview
- Safety Profile
- Efficacy Profile
- MarketDifferentiation
- IP Diligence
- Competitive Landscape
- Regulatory Path
- Development
 Plan

Step IV: Primary Analysis

- Commercial Expertise
- Industry Input
- InvestorInputRegulatoryInput
- Payer Interviews
- Third-party scientific expertise

Commercial Relevance

- Investment
- Partnerships
- Funding
- SBIR/STTR
- NIH Collaboration
- JointVentures
- Licenses



BHI News & Website



BHI Web site

The BHI Web site has news, an events calendar, research publications, regional organization feature stories and resources for the biohealth industry.

http://www.biohealthinnovation.org



BHI News

BHI's weekly e-newsletter highlights the Central Maryland Region's news articles, national biohealth trends and feature stories.

http://www.biohealthinnovation.org/news







Innovation Resource Guide

"Financing and Entrepreneurial Resource for Montgomery County and the Greater Baltimore Region"

- **Entrepreneur and Innovation** Resource Network
- Innovator Financing Guide
- The Startup's Guide to **Intellectual Property**



Central Maryland Biohealth Entrepreneur's Resource and Finance Guide

- Provides businesses and entrepreneurs with information to access resources necessary to grow their biohealth businesses.
- A-Z directory of relevant businesses, organizations and resources for business assistance, economic development, innovation research, Investment and technical assistance
- A comprehensive financing guide designed to prepare businesses and entrepreneurs to navigate the complicated world of
- A startup's guide to intellectual property that will introduce entrepreneurs to the complex issues surrounding patents. trademarks, copyrights and trade secrets.
- The guide will be free and available in both print and electronic





Benefits of Inclusion:

- Exposure to businesses, entrepreneurs, nonprofit organizations and government leaders.
- Opportunity to market assistance and investment programs to a large audience.

Benefits of Sponsorship:

- Company logo printed on the inside cover of the guide.
- Exposure to 1,000s of businesses, organizations and government leaders through distribution of the

Benefits of Advertisement:

- Half-to-full-page detailed ads available to market your company or organization.
- Exposure to 1,000s of businesses, organizations and government leaders through distribution of the

To advertise, sponsor or be included in the guide, please contact:


Michael Combs Economic Alliance of Greater Baltimore 410-637-4105 mcombs@greaterbaltimore.org



Central Maryland Biohealth Entrepreneur's Resource and Finance Guide is a joint effort between BioHealth Innovation and the Economic Alliance of Greater Baltimore.

For more information, visit:

www.biohealthinnovation.org www.greaterbaltimore.org





BHI Innovation Capital

- SBIR/STTR Assistance Program The BHI SBIR/STTR Assistance Program (in development) will provide assistance to biohealth-driven companies in the Central Maryland region in preparing for high-quality SBIR/STTR grant proposals for submission to federal funding agencies.
- BHI Angel Fund The BHI Angel Fund (in development) will be a member-managed private equity investment fund that bridges the gap between pre-seed investments and institutional venture capital serving the Central Maryland region entrepreneurial needs.
- BHI Commercial Relevance Investment Fund The BHI Commercial Relevance Investment Fund (in development) will be a pre-seed and early-stage, equity-based innovation capital fund to help grow, attract, retain and connect Central Maryland biohealth innovation-based companies that need financing to grow their enterprises.



How is Success Measured? BHI Metrics – First 5 Years

	Now	In 5 Years
VC Funding for Biotech	\$79 Million	\$150
Government Funding for Biotech	Increased SBIR proposals & success	Improve Maryland's ranking
Source Prospective Deals Annually	30	150

Improve return on R&D investment by leveraging equity investment

Create and retain 1,300 jobs

Recruit entrepreneurs, experienced managers and businesses

Commercialize biohealth technologies and create biohealth companies



BHI: The Triple Bottom Line

Grows high-paying jobs and businesses

Expands tax base; improves economic vitality

...and Benefits human health!



BHI Staff

Richard Bendis

President & CEO (215) 593-3333 rbendis@bendisig.com

Renée Enright

Executive Administrator (301) 637-5372 renright@biohealthinnovation.org

Todd Chappell

Entrepreneur-In-Residence (978) 933-1622 tchappell@biohealthinnovation.org

Amanda Wilson

Operations Manager (301) 637-0699 awilson@biohealthinnovation.org

Ethan Byler

Director, Innovation Programs (301) 637-7952 ebyler@biohealthinnovation.org

Adam Hafez

Student Intern
(301) 637-7270
ahafez@biohealthinnovation.org

BioHealth Innovation, Inc.

22 Baltimore Road | Rockville, MD 20850

bhi@biohealthinnovation.org



